tmem65 Antibody

What is TMEM65 and where is it localized in the cell?

TMEM65 (transmembrane protein 65) is a 240 amino acid protein with a calculated molecular weight of approximately 26 kDa, though it is typically observed at 18-25 kDa in experimental conditions . Subcellular fractionation studies have definitively confirmed that TMEM65 is localized to the inner mitochondrial membrane . This localization has been verified through immunofluorescence staining showing co-localization with mitochondrial-targeted stains . The protein's mitochondrial localization is consistent across multiple cell types, including fibroblasts, which are frequently used in mitochondrial research due to their accessibility and ease of culture . The precise topology and orientation of TMEM65 within the inner mitochondrial membrane remains an active area of investigation, with implications for understanding its functional interactions with other mitochondrial proteins.

Which applications are most effective for TMEM65 antibody detection?

TMEM65 antibodies have been validated across multiple applications with varying sensitivity and specificity profiles. Western blot (WB) analysis demonstrates particularly robust detection, with recommended dilutions ranging from 1:5000 to 1:50000, indicating high sensitivity of available antibodies . Immunohistochemistry (IHC) applications are effective at dilutions of 1:500-1:2000, while immunofluorescence/immunocytochemistry (IF/ICC) typically requires 1:200-1:800 dilutions for optimal signal-to-noise ratio . When selecting an application, researchers should consider that TMEM65 antibodies have been positively validated in the following experimental systems:

It is imperative that researchers perform appropriate optimization in their specific experimental system regardless of these recommendations .

What are the critical storage conditions for maintaining TMEM65 antibody activity?

TMEM65 antibodies require specific storage conditions to maintain their binding efficacy and specificity. The recommended storage is at -20°C, where the antibodies remain stable for one year after shipment . The antibodies are typically supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain protein stability during freeze-thaw cycles . Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling procedures . Some commercial preparations of the antibody (particularly at 20μl volumes) may contain 0.1% BSA as an additional stabilizing agent . Researchers should note that sodium azide is a preservative that inhibits bacterial growth but is also toxic and potentially explosive when combined with heavy metals; therefore, proper disposal protocols should be followed .

How does TMEM65 knockdown affect mitochondrial function?

TMEM65 knockdown experiments using siRNA have revealed critical insights into its functional importance in mitochondrial physiology. When TMEM65 expression is reduced in dermal fibroblasts, researchers observe severe impairment of mitochondrial content and substantial reduction in cellular respiration rates . These findings suggest that TMEM65 plays an essential role in maintaining mitochondrial respiratory chain function, rather than serving merely as a structural protein .

Specific experimental outcomes of TMEM65 knockdown include:

• Decreased abundance of respiratory chain complex proteins

• Reduced oxygen consumption rate in intact cells

• Altered mitochondrial morphology

• Impaired energy production capacity

These effects parallel the mitochondrial dysfunction observed in patient cells harboring a homozygous splice variant (c.472+1G>A) in the TMEM65 gene, providing corroborating evidence for the protein's critical role in mitochondrial function . For researchers designing knockdown experiments, it is recommended to include measurements of multiple parameters of mitochondrial function, including enzymatic activities of respiratory chain complexes, oxygen consumption rates, and mitochondrial membrane potential, to comprehensively characterize the resulting phenotype .

What role does TMEM65 play in disease pathogenesis?

TMEM65 has been implicated in at least two distinct disease processes: mitochondrial encephalomyopathy and gastric cancer.

In mitochondrial disease, a homozygous splice variant (c.472+1G>A) in the TMEM65 gene results in severe mitochondrial dysfunction and a clinical presentation of mitochondrial encephalomyopathy . This finding established TMEM65 as a nuclear-encoded gene essential for mitochondrial function, with mutations leading to a primary mitochondrial disease phenotype. The clinical manifestations in affected patients highlight the tissue-specific importance of TMEM65, particularly in high-energy-demanding tissues like brain and muscle .

In cancer biology, TMEM65 shows notable oncogenic properties in gastric cancer models. Copy number alterations of TMEM65 have been identified as crucial events in gastric cancer development, with amplification of the TMEM65 gene resulting in increased mRNA levels . This overexpression correlates with poor prognosis in gastric cancer patients . Mechanistically, ectopic expression of TMEM65 promotes cell proliferation, cell cycle progression, and invasion/migration capabilities while inhibiting apoptosis . The dual involvement of TMEM65 in both mitochondrial disease and cancer highlights the diverse functional roles of this protein and suggests context-dependent regulation of its activity.

What molecular mechanisms explain TMEM65's role in oncogenesis?

TMEM65 exerts its oncogenic effects in gastric cancer through specific molecular interactions with key signaling pathways. Research has revealed that TMEM65 activates the PI3K-Akt-mTOR signaling pathway, as evidenced by increased phosphorylation of key regulators including p-Akt, p-GSK-3β, and p-mTOR . This pathway is a central regulator of cell growth, proliferation, and survival, and its hyperactivation is a hallmark of many cancers.

Mechanistically, TMEM65 has been identified to interact directly with YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase) in the cytoplasm . This physical interaction inhibits the ubiquitin-mediated degradation of YWHAZ, thereby stabilizing this protein . YWHAZ serves as a direct downstream effector of TMEM65, and experimental evidence suggests that the oncogenic effect of TMEM65 is partially dependent on YWHAZ expression .

For researchers investigating the oncogenic mechanisms of TMEM65, several experimental approaches have yielded valuable insights:

• In vitro cellular functional assays (proliferation, migration, invasion, apoptosis)

• In vivo tumor growth and metastasis models

• Protein-protein interaction studies (co-immunoprecipitation)

• Ubiquitination assays to assess protein stability

• Phosphoprotein analysis to assess pathway activation

• Therapeutic targeting using siRNA-loaded nanoparticles (VNP-encapsulated TMEM65-siRNA)

These approaches collectively demonstrate that TMEM65 overexpression contributes to gastric tumorigenesis through specific pathway alterations, suggesting its potential as both a biomarker and therapeutic target in gastric cancer .

How can researchers effectively validate TMEM65 antibody specificity?

Ensuring antibody specificity is critical for reliable TMEM65 research. A comprehensive validation approach should include multiple complementary strategies:

• Genetic knockdown/knockout controls: siRNA-mediated knockdown of TMEM65 should result in reduced or absent signal in Western blots and immunostaining experiments. This represents the gold standard for antibody validation .

• Multiple antibody comparison: Utilizing antibodies from different sources or those targeting different epitopes of TMEM65 (such as 21913-1-AP and 83219-4-RR) can provide confirmation of specificity when similar patterns are observed .

• Subcellular fractionation: Given TMEM65's mitochondrial localization, proper validation should show enrichment in mitochondrial fractions and absence in other cellular compartments .

• Mass spectrometry verification: For ultimate confirmation, immunoprecipitation followed by mass spectrometry can verify the identity of the protein being detected.

• Recombinant protein controls: Using purified or overexpressed TMEM65 as a positive control can help establish the correct molecular weight and antibody performance characteristics.

Researchers should be aware that TMEM65 has an expected molecular weight of 26 kDa based on its amino acid sequence, but is typically observed between 18-25 kDa in experimental conditions, likely due to post-translational modifications or processing . This discrepancy between calculated and observed molecular weights should be considered when evaluating antibody specificity.

What are the methodological considerations for studying TMEM65 in different tissues?

Investigating TMEM65 across various tissues requires tailored methodological approaches to address tissue-specific challenges:

• Tissue selection and preservation: TMEM65 antibodies have been validated in various tissues including brain, colon cancer tissue, and multiple cell lines . For each tissue type, optimal fixation methods should be established - for example, with human colon cancer tissue, antigen retrieval with TE buffer pH 9.0 is suggested, with citrate buffer pH 6.0 as an alternative .

• Cell type heterogeneity: In complex tissues like brain, where TMEM65 has been successfully detected , researchers should consider cell type-specific expression patterns through co-staining with cell type markers.

• Mitochondrial content variation: Since TMEM65 is a mitochondrial protein, interpretation of expression levels should account for differences in mitochondrial content between tissues. Normalization to mitochondrial markers (e.g., VDAC, TOM20) rather than just housekeeping genes is recommended.

• Application-specific optimizations:

  • For Western blotting: Sample preparation protocols should be optimized for mitochondrial protein extraction

  • For immunohistochemistry: Antigen retrieval methods significantly impact TMEM65 detection and should be empirically determined for each tissue type

  • For immunofluorescence: Co-staining with mitochondrial markers helps confirm proper localization

• Disease state considerations: In pathological conditions like cancer or mitochondrial disease, TMEM65 localization or abundance may be altered . Paired normal/diseased tissue comparisons provide important controls.

These methodological considerations enable robust cross-tissue comparisons of TMEM65 expression and function, critical for understanding its tissue-specific roles in health and disease contexts.

What controls should be incorporated when using TMEM65 antibodies?

Rigorous experimental design requires appropriate controls to ensure reliable interpretation of TMEM65 antibody results:

• Positive controls: Include samples known to express TMEM65, such as HEK-293 cells, HeLa cells, mouse brain tissue, or rat brain tissue, which have been validated for positive detection .

• Negative controls:

  • Primary antibody omission control to assess non-specific binding of secondary antibodies

  • Isotype control (rabbit IgG) to evaluate non-specific binding due to Fc receptor interactions

  • Tissue known to lack TMEM65 expression

  • TMEM65 knockdown samples generated through siRNA treatment

• Loading controls:

  • For whole cell lysates: Standard housekeeping proteins (β-actin, GAPDH)

  • For mitochondrial studies: Mitochondrial markers (VDAC, TOM20, COX IV) to normalize for mitochondrial content

• Subcellular localization controls: Co-staining with established mitochondrial markers for immunofluorescence studies to confirm proper localization .

• Antibody validation controls:

  • Peptide competition assay to confirm specificity

  • Testing multiple TMEM65 antibodies targeting different epitopes

Incorporating these controls ensures that experimental findings can be confidently attributed to specific TMEM65 detection rather than technical artifacts or non-specific interactions.

How should researchers address discrepancies in TMEM65 molecular weight observations?

TMEM65 exhibits variability in observed molecular weight across different experimental systems, which requires careful interpretation:

• Expected versus observed molecular weight: TMEM65 has a calculated molecular weight of 26 kDa based on its 240 amino acid sequence, but is typically observed at 18-25 kDa in Western blot applications . This discrepancy might be attributed to:

  • Post-translational modifications

  • Proteolytic processing

  • Anomalous migration due to hydrophobic transmembrane domains

• Verification approaches:

  • Use of recombinant TMEM65 protein as a size reference

  • Analysis of TMEM65 knockdown samples to confirm band identity

  • Mass spectrometry verification of immunoprecipitated protein

  • Comparison of results using multiple antibodies targeting different epitopes

• Technical considerations:

  • Gel percentage and running conditions can impact apparent molecular weight

  • Sample preparation methods, particularly for membrane proteins, may affect migration patterns

  • Use of gradient gels may improve resolution in the relevant molecular weight range

• Documentation practices: Researchers should clearly report both the calculated and observed molecular weights in publications, along with details of sample preparation and electrophoresis conditions .

When working with a novel cell line or tissue sample, validation of the specific TMEM65 band is particularly important given these known molecular weight variations across experimental systems.

What approaches can be used to study TMEM65 protein-protein interactions?

Understanding TMEM65's functional relationships requires investigating its protein-protein interactions through multiple complementary techniques:

• Co-immunoprecipitation (Co-IP): This approach has successfully identified TMEM65's interaction with YWHAZ in gastric cancer cells . When designing Co-IP experiments:

  • Use antibodies validated for immunoprecipitation

  • Include appropriate negative controls (IgG, irrelevant antibody)

  • Consider crosslinking for transient interactions

  • Validate results in reverse Co-IP configuration

• Proximity ligation assay (PLA): This technique can visualize and quantify protein interactions in situ with high sensitivity and specificity, particularly valuable for membrane proteins like TMEM65.

• FRET/BRET approaches: For studying dynamic interactions in living cells, fluorescence or bioluminescence resonance energy transfer techniques provide temporal information about TMEM65 interactions.

• BioID or APEX2 proximity labeling: These approaches can identify the broader interaction network of TMEM65 within the mitochondrial membrane environment.

• Yeast two-hybrid screening: While challenging for transmembrane proteins, modified membrane yeast two-hybrid systems can be applied to identify novel TMEM65 interactors.

• Mass spectrometry-based approaches:

  • Immunoprecipitation followed by mass spectrometry

  • Crosslinking mass spectrometry for capturing transient interactions

  • Stable isotope labeling by amino acids in cell culture (SILAC) for quantitative comparison

Research has demonstrated that TMEM65 physically interacts with YWHAZ in the cytoplasm, inhibiting ubiquitin-mediated degradation of YWHAZ . This finding highlights the importance of investigating interactions both within the mitochondria and potentially in other cellular compartments.

What emerging technologies might advance TMEM65 research?

Several cutting-edge technologies hold promise for deepening our understanding of TMEM65 biology:

• CRISPR-Cas9 genome editing: Generation of TMEM65 knockout or knock-in cell lines and animal models will provide more definitive insights into its function than traditional siRNA approaches . CRISPR-based technologies enable:

  • Complete protein elimination rather than knockdown

  • Introduction of patient-specific mutations

  • Tagging of endogenous TMEM65 with fluorescent or affinity tags

• Cryo-electron microscopy: This technology could reveal the structural integration of TMEM65 within mitochondrial membrane complexes, providing insights into its functional interactions within the inner mitochondrial membrane .

• Single-cell analyses: Single-cell transcriptomics and proteomics can reveal cell-type specific expression patterns and heterogeneity in TMEM65 levels across tissues and disease states.

• Organoid models: Patient-derived organoids carrying TMEM65 mutations could serve as improved disease models compared to traditional 2D cell culture.

• Therapeutic targeting approaches: Novel delivery systems like those used for TMEM65-siRNA (VNP-encapsulated) may enable targeted therapeutic intervention for TMEM65-related diseases.

• Live cell imaging techniques: Super-resolution microscopy combined with specific TMEM65 tagging could reveal dynamic aspects of its localization and function within mitochondria.

• Multi-omics integration: Combining genomic, transcriptomic, proteomic, and metabolomic data will provide a systems-level understanding of TMEM65's role in cellular physiology and disease.

These emerging technologies promise to address current knowledge gaps regarding TMEM65's precise molecular function, tissue-specific roles, and therapeutic targeting potential.

How do TMEM65 expression patterns differ across developmental stages and disease progression?

Understanding the temporal dynamics of TMEM65 expression remains an important research frontier. Current evidence suggests significant variations that warrant systematic investigation:

• Developmental expression patterns:

  • Limited data exists on TMEM65 expression during embryonic and postnatal development

  • The severity of phenotypes in patients with TMEM65 mutations suggests important developmental roles

  • Systematic profiling across developmental timepoints could reveal critical periods of TMEM65 function

• Disease progression correlations:

  • In gastric cancer, TMEM65 expression correlates with disease progression and patient survival

  • High TMEM65 expression or DNA copy number predicts poor prognosis in gastric cancer patients

  • Longitudinal studies tracking TMEM65 levels through disease progression could establish its utility as a biomarker

• Tissue-specific expression regulation:

  • TMEM65 has been detected in various tissues including brain, with particularly important functional roles in high-energy-demanding tissues

  • Research is needed to understand tissue-specific regulatory mechanisms controlling TMEM65 expression

  • Epigenetic regulation of TMEM65 expression remains largely unexplored

• Experimental approaches:

  • Immunohistochemistry on tissue microarrays spanning multiple developmental stages

  • Reporter gene constructs to monitor TMEM65 promoter activity

  • Analysis of public single-cell RNA-seq datasets across tissues and developmental timepoints

  • Longitudinal sampling in disease progression models

These investigations would provide crucial insights into when and where TMEM65 functions are most critical, potentially identifying windows for therapeutic intervention in TMEM65-associated diseases.